Effect of acetazolamide on the differential threshold

Area of Science:

• Ophthalmology
• Pharmacology

Background:

• Glaucoma is a leading cause of irreversible blindness.
• Visual field defects are a key indicator of glaucoma progression.
• Acetazolamide is a carbonic anhydrase inhibitor with potential ocular hypotensive effects.

Purpose of the Study:

• To evaluate the effect of acetazolamide sodium on visual field defects in glaucoma patients.
• To compare the response in glaucoma patients versus glaucoma suspects.

Main Methods:

• Oral administration of three 250-mg doses of acetazolamide sodium.
• Assessment of differential visual field threshold in nine glaucoma patients and 16 glaucoma suspects.

Main Results:

• Statistically significant improvement in differential threshold observed in glaucoma patients.
• No significant change detected in glaucoma suspects.
• Greatest improvements in glaucoma patients were noted in younger individuals and those with more severe visual field disturbances.

Conclusions:

• Acetazolamide sodium demonstrates a therapeutic effect on glaucomatous visual-field defects.
• The drug's efficacy appears dependent on disease severity and patient age.
• Acetazolamide sodium may be a beneficial treatment option for specific glaucoma patient subgroups.